Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SSS11 in Patients With Gout and Hyperuricemia
NCT06629376Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SSS11 in gout and hyperuricemia (6 arms), sponsored by 3SBio. Primary endpoint: Safety and Tolerability at 12 weeks. Started Nov 2023; status: recruiting.
02
Drugs
SSS11
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06629376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629376.